India Pharma Outlook Team | Wednesday, 20 August 2025
Glenmark Pharmaceuticals Inc. is officially announced to implement the launch1 of Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial) from Glenmark Pharmaceuticals Inc., USA (Glenmark).
The reference listed medication, Mycamine for Injection, 50 mg/vial and 100 mg/vial of Astellas Pharma US, Inc. NDA-021506, is bioequivalent and therapeutically equivalent to Glenmark's Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial). The company plans to start distribution in September 2025.
According to IQVIA sales data for the 12-month period ending June 2025, the Mycamine for Injection, 50 mg/vial and 100 mg/vial market experienced annual sales of about $60.7 million.
Commenting on the Glenmark Pharmaceuticals launch, Marc Kikuchi, President & Business Head, North America said, "We are excited to announce the launch of Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial), growing our portfolio of products within the institutional channel, while also strengthening our commitment to bring quality and affordable alternatives to market for patients in need."
Also Read: Lupin launched Glucagon for injection USP, 1 mg/Vial
The only indications for which Glenmark's Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial), is approved are those specified on the label. With a focus on respiratory, dermatological, and oncological therapies, Glenmark Pharmaceuticals Limited is a research-driven, multinational pharmaceutical firm that operates in the branded, generic, and over-the-counter markets. The company has four research and development facilities, 10 state of the art manufacturing operations on 5 continents, and operations in more than 80 countries.
